NewAmsterdam Pharma Company N.V.
NAMS
$36.47
-$3.98-9.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 740.06% | 112.56% | 1,490.54% | 889.83% | 32.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 740.06% | 112.56% | 1,490.54% | 889.83% | 32.73% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 740.06% | 112.56% | 1,490.54% | 889.83% | 32.73% |
| SG&A Expenses | 65.49% | 87.86% | 99.40% | 101.71% | 67.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.13% | 26.41% | 7.95% | 3.08% | 24.11% |
| Operating Income | 32.22% | -24.23% | 15.36% | 49.55% | -23.76% |
| Income Before Tax | 55.48% | 57.85% | -86.34% | 64.68% | -1.87% |
| Income Tax Expenses | -- | -- | -100.00% | -- | -- |
| Earnings from Continuing Operations | 55.48% | 57.85% | -86.23% | 64.68% | -1.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.48% | 57.85% | -86.23% | 64.68% | -1.87% |
| EBIT | 32.22% | -24.23% | 15.36% | 49.55% | -23.76% |
| EBITDA | 32.28% | -24.17% | 15.44% | 49.59% | -23.75% |
| EPS Basic | 64.43% | 67.91% | -54.47% | 69.26% | 11.72% |
| Normalized Basic EPS | 67.06% | 61.07% | -32.81% | 72.18% | 3.88% |
| EPS Diluted | 64.43% | 67.91% | -54.47% | 69.26% | 11.72% |
| Normalized Diluted EPS | 67.06% | 61.07% | -32.81% | 72.18% | 3.88% |
| Average Basic Shares Outstanding | 25.18% | 31.39% | 20.56% | 14.90% | 15.41% |
| Average Diluted Shares Outstanding | 25.18% | 31.39% | 20.56% | 14.90% | 15.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |